International Stem Cell Corp., a biotechnology company focused on therapeutic and biomedical products using human parthenogenetic stem cells (hpSCs), reported today that Dr. Ruslan Semechkin, VP of Research and Development, will be presenting additional data from the primate study of the use of neuronal cells for the treatment of Parkinson’s disease at the 16th Annual Meeting of American Society of Gene and Cell Therapy, May 15-18, 2013, at the Salt Palace Convention Center in Salt Lake City, UT.
The results, including detailed information on the safety and functional activity of the cells, will be presented at the following session:
Session: Stem Cell Engineering and Therapy
Date: Thursday, May 16, 2013
Time: 2:00 PM
Room: Ballroom D
Title: Cell Replacement Therapy for Parkinson’s Disease with Neuronal Cells Derived from Human Parthenogenetic Stem Cells
ISCO will additionally present two posters describing the progress taking place in its pre-clinical metabolic liver disease program and recent achievements with its “safe” iPS cells, induced pluripotent stem cells that do not rely on viral vectors for the genetic reprogramming. The posters will be presented on Thursday, May 16, 2013, between 4:00 pm and 6:00 pm in Exhibit Hall C/D.
For more information on International Stem Cell Corp., visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment